Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 632
Aptamer sequence: GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC
Target unique ID: 681
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_598 dopa2/c.1 Molecule Dopamine 1.6 μM 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, and 0.5 M or 0.15 M NaCl 9245404
Structure information of aptamer
Aptamer Sequence: GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC
The optimal secondary structure in dot-bracket notation: .....(((((((.......)))))))..(((((..(((.......))).)))))((((....((.((((..(((...))).))))))..))))
The centroid secondary structure in dot-bracket notation: ((((.(((((((.......)))))))..(((((..(((.......))).))))).........(.((((..(((...))).)))))...))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_598 Description dopa2/c.1
Aptamer chemistry RNA Length 93 nt
GC content 58.1% Molecular weight 30,111.99 Da
Molarity of 1 μg/μl solution 33.21 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Aptasensor
Sequence GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC
Applications Detection of dopamine
Target information
Type Detail Type Detail
PubChem ID 681 Molecular name Dopamine
Molecular formula C8H11NO2 Molecular weight 153.18
IUPAC name 4-(2-aminoethyl)benzene-1,2-diol InChIKey VYFYYTLLBUKUHU-UHFFFAOYSA-N
LogP 0.599 Topological polar surface area 66.48
Hydrogen bond acceptor 3 Hydrogen bond donor 3

Synonym(s):
dopamine; 4-(2-Aminoethyl)benzene-1,2-diol; 3-Hydroxytyramine; 51-61-6; Dopamin; Hydroxytyramin; Oxytyramine; 3,4-dihydroxyphenethylamine; intropin; Dophamine; 2-(3,4-dihydroxyphenyl)ethylamine; 4-(2-Aminoethyl)catechol; hydroxytyramine; Dopaminum; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)-1,2-benzenediol; 3,4-Dihydroxyphenylethylamine; Dopamina; L-DOPAMINE; ASL 279; Pyrocatechol, 4-(2-aminoethyl)-; 1,2-Benzenediol, 4-(2-aminoethyl)-; Dopaminum [INN-Latin]; Dopamina [INN-Spanish]; 3-Hydroxtyramine; alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; KW-3-060; Sinemet; 4-(2-aminoethyl)-pyrocatechol; UNII-VTD58H1Z2X; Dynatra; NSC 173182; a-(3,4-Dihydroxyphenyl)-b-aminoethane; 4-(2-Aminoethyl)-1,2-bezenediol; VTD58H1Z2X; CHEBI:18243; NSC-173182; LDP; NCGC00015519-05; Pyrocatechol, 4-(2-aminoethyl)- (8CI); Dopamine [INN:BAN]; DSSTox_CID_2420; 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI); DSSTox_RID_76584; DSSTox_GSID_22420; .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane; 1,2-Benzenediol, 4-(2-aminoethyl)-, homopolymer; (3H)-Dopamine; Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; 62-31-7 (HYDROCHLORIDE); CAS-51-61-6; Dopamine (INN); 86389-83-5; Medopa (TN); NSC169105; HSDB 3068; EINECS 200-110-0; Intropin [*hydrochloride*]; 4-(2-Aminoethyl)-1,2-benzenediol hydrochloride; SR-01000075366; .beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; m-Hydroxytyramine-; Dopamine (USAN)(*hydrochloride*); IP 498; Intropin (Salt/Mix); Spectrum_001012; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; CHEMBL59; Spectrum2_001023; Spectrum3_000406; Spectrum4_000525; Spectrum5_000945; Lopac-H-8502; Biomol-NT_000001; bmse000909; bmse000933; SCHEMBL8505; 1, 4-(2-aminoethyl)-; Lopac0_000586; Oprea1_088821; BSPBio_001932; GTPL940; KBioGR_001129; KBioGR_002388; KBioGR_002484; KBioSS_001492; KBioSS_002393; KBioSS_002491; cid_65340; BIDD:ER0506; DivK1c_000780; SPECTRUM1505155; SPBio_001205; BPBio1_001123; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; DTXSID6022420; BDBM55121; KBio1_000780; KBio2_001492; KBio2_002388; KBio2_002484; KBio2_004060; KBio2_004956; KBio2_005052; KBio2_006628; KBio2_007524; KBio2_007620; KBio3_001152; KBio3_002867; KBio3_002962; ZINC33882; cMAP_000036; cMAP_000065; NINDS_000780; HMS3743I03; AMY40803; BCP34189; Tox21_110167; 2-(3, 4-Dihydroxyphenyl)ethylamine; 2-(3,4-dihydroxyphenyl) ethylamine; BBL013043; MFCD00130258; NSC173182; STK301601; 3,4-DihydroxyphenylA currencythylamin; AKOS003790978; Tox21_110167_1; CCG-204675; DB00988; FS-5341; MCULE-7558764100; SDCCGSBI-0050568.P005; 2-(3,4-Dihydroxyphenyl)-1-ethanamine; 4-(2-Amino-ethyl)-benzene-1,2-diol; 4-(2-Aminoethyl)-1,2-benzenediol #; IDI1_000780; UPCMLD0ENAT5885989:001; NCGC00015519-01; NCGC00015519-02; NCGC00015519-03; NCGC00015519-04; NCGC00015519-07; NCGC00015519-08; NCGC00015519-09; NCGC00015519-10; NCGC00015519-11; NCGC00015519-25; NCGC00096050-01; NCGC00096050-02; NCGC00096050-03; NCGC00096050-04; NCGC00096050-05; 50444-17-2; BP-23276; 4-(2-aminoethyl)pyrocatechol;hydrochloride; SBI-0050568.P004; FT-0698513; 2-(4-Hydroxy-5-oxylatophenyl)-1-ethanaminium; C03758; D07870; F21485; 13510-EP2269989A1; 13510-EP2270011A1; 13510-EP2272537A2; 13510-EP2272825A2; 13510-EP2272847A1; 13510-EP2275420A1; 13510-EP2277882A1; 13510-EP2280010A2; 13510-EP2281559A1; 13510-EP2281815A1; 13510-EP2281819A1; 13510-EP2284169A1; 13510-EP2284170A1; 13510-EP2284171A1; 13510-EP2286811A1; 13510-EP2287161A1; 13510-EP2287162A1; 13510-EP2287165A2; 13510-EP2287166A2; 13510-EP2292620A2; 13510-EP2295437A1; 13510-EP2295439A1; 13510-EP2298312A1; 13510-EP2298313A1; 13510-EP2298731A1; 13510-EP2298734A2; 13510-EP2298758A1; 13510-EP2298759A1; 13510-EP2298775A1; 13510-EP2298776A1; 13510-EP2301540A1; 13510-EP2301933A1; 13510-EP2305260A1; 13510-EP2305633A1; 13510-EP2305640A2; 13510-EP2305644A1; 13510-EP2305648A1; 13510-EP2305650A1; 13510-EP2305652A2; 13510-EP2305656A1; 13510-EP2305659A1; 13510-EP2305664A1; 13510-EP2305675A1; 13510-EP2305689A1; 13510-EP2308828A2; 13510-EP2308867A2; 13510-EP2308870A2; 13510-EP2308875A1; 13510-EP2311494A1; 13510-EP2311801A1; 13510-EP2311802A1; 13510-EP2311803A1; 13510-EP2311818A1; 13510-EP2311827A1; 13510-EP2311828A1; 13510-EP2311835A1; 13510-EP2314571A2; 13510-EP2316470A2; 13510-EP2316836A1; 13510-EP2371814A1; 4-(2-azanylethyl)benzene-1,2-diol;hydrochloride; AB00053463-12; AB00053463_13; AB00053463_14; L000232; Q170304; SR-01000075366-7; Oseltamivir-d3;Hydroxytyramin;4-(2-Aminoethyl)benzene-1,2-diol

Activity data

No relevant experimental diagram

 Interaction ID 632
Target type Molecule
Target unique ID 681
Activity 1.6 μM
Binding Conditions/Buffer

50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, and 0.5 M or 0.15 M NaCl
Assay

N/A
PubMed ID 9245404
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_601 RNA GGGAAUUCCGCGUGUGCGCCGCGGAAGAGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC 72.04%
Apta_353 RNA GAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCAGGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCC 55.91%
Apta_885 RNA GGGAGAGCGGAAGCGUGCUGGGCCUGGUUGCUGUAAAAAUAGACACGAAUCUGCCGACCAUAACCCAGAGGUCGAUGGAUCCCCCC 53.76%
Apta_1054 RNA CUGACGUUUCGAACGUCAAAUGCGGAAGUUGUCGGAGCUAAGAAACGGGUAAUGAUGCCGUUGAUGUGAAGGCGGGCUCA 53.76%
Apta_599 RNA GUCUCUGUGUGCGCCAGAGAACACUGGGGCAGAUAUGGGCCAGCACAGAAUGAGGCCC 52.69%
Apta_854 RNA GGGAGCUCAGAAUAAACGCUCAAGGGUAGGGAUCGUUACCCCGACAUUUUAAUGGGCCGAUGUUUCGACAUGAGGCCCGGAUCCGGC 52.69%
Apta_599 RNA GUCUCUGUGUGCGCCAGAGAACACUGGGGCAGAUAUGGGCCAGCACAGAAUGAGGCCC 52.69%
Apta_383 RNA GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC 51.61%
Apta_382 RNA GGCGUGACCUGAUGAGUCACGCAGACGCUAGCGAAUUGGUUCCUCGAAAGGGGAAAGCGUUAUUAAGAAACCAAAAUGUGUUACGAAACGUUCCC 51.58%
Apta_376 RNA GGGAGCUCAGCCUUCACUGCACUCCGGCUGGUGGACGCGGUACGAGCAAUUUGUACCGGAUGGAUGUUCGGGCAGCGGUGUGGCAGGGAUGAGCGGCACCACGGUCGGAUCCAC 50.88%
Apta_415 RNA GGGAGGACGAUGCGGAAACUCAUCGGUAGCCUUCCUGCGGUCAGUCUAUUAGGACCAGACGACUCGCUGAGGAUCCGAGA 50.54%
Apta_460 RNA GGAUGGCAGCGGAGAGUUGCUUGGAAUGCGUUAUAGUCUCUUAGGUGUGUACAGCCCACACCACUCUCC 50.54%
Apta_496 RNA GGGCUAGCUGAUCGUACCCAGUAGCGUGGCAUGGGGUGCCUAGUCGGGCGAUACUAACAGCUAACACCC 50.54%
Apta_984 RNA GGGAGGACGAUGCGGCGUAUUGCGCGAGGAUUAUCCGCUCAUCGUUGUUGUUGUGCAGACGACUCGCCCGA 50.54%
Apta_936 RNA GGAGCUCAGCCUUCACUGCGAUCACCGUGUCGGUGGCUAGUCGAUGUAUCCCGAUCACCAUUGGGGGCAAGUUUAGACAGGCACCACGGUCGGAUCCAC 50.51%
Apta_280 RNA GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGCAGAAAAGGGGGAAGAAGAGGGUGAUUCAGGCGAGAGAAUGGAUCCACAUCUACGAAUUC 50.47%
Apta_494 RNA GGGAGAUACCAGCUUAUUCAAUUCUGGCAAUGGGCUAUCCCAAGUGCUAGGCUUCAGGGAGCGAGGACCAGACGACGUACCUAACCCUAAGGUGAGAUAGUAAGUGCAAUCU 50.00%
Apta_557 RNA GGAACACUAUCCGAUGGCACCGACCAUAGGCUCGGGUUGCCAGAGGUUCCACACUUUCAUCGAAAAGCCUAUGCUAGGCAAUGACAUGGACUCCUUGGUCAUUAGGAUCG 50.00%
Apta_874 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUAGGAUAUGUCUGGAUACCAUGCAUGAUGCACCUUGGCAGUCUUACAGAAGGACGUCGAAACGGUAGCGAGAGCUC 49.57%
Apta_720 RNA GGGAGAAUUCCGACCAGAAGCUUAGUAUAGCGAGGUUUAGCUACACUCGUGCUGAUCGUUUGGUACGGGACCUGCGUGUAGCCCAUAUGUGCGUCUACAUGGAUCCUCA 49.54%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43982
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.